Suggested remit: To appraise the clinical and cost effectiveness of cemiplimab within its marketing authorisation for untreated PD-L1 positive advanced or metastatic non-small cell lung cancer with no EGFR, ALK or ROS-1 mutations.
Status In progress
Process STA 2018
ID number 3839

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
19 January 2021 - 16 February 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
18 March 2019 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance